UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Optimization of Pretreatment Conditions and Enzymatic Hydrolysis of Corn Cobs for Production of Microbial Lipids by Trichosporon oleaginosus

Energies (Basel), 2022-05, Vol.15 (9), p.3208

2022

Volltextzugriff (PDF)

Lipid production by Mortierella isabellina from pretreated corn cobs and effect of lignocellulose derived inhibitors on growth and lipid synthesis

Process biochemistry (1991), 2021-10, Vol.109, p.46-58

2021

Volltextzugriff (PDF)

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Journal of headache and pain, 2021-12, Vol.22 (1), p.68-68, Article 68

2021

Volltextzugriff (PDF)

Selenite as a Lipid Inductor in Marine Microalga Dunaliella tertiolecta: Comparison of One-Stage and Two-Stage Cultivation Strategies

Applied biochemistry and biotechnology, 2022-02, Vol.194 (2), p.930-949

2022

Volltextzugriff (PDF)

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

Journal of headache and pain, 2021-12, Vol.22 (1), p.152-152, Article 152

2021

Volltextzugriff (PDF)

Nanosized zeolite beta - Determining the safety of usage by zebrafish Danio rerio embryos

Microporous and mesoporous materials, 2020-06, Vol.299, p.110103, Article 110103

2020

Volltextzugriff (PDF)

Minor neurological dysfunction in children aged 5 to 7

Vojnosanitetski pregled, 2018-01, Vol.75 (8), p.815-819

2018

Volltextzugriff (PDF)

Secretory antibodies reduce systemic antibody responses against the gastrointestinal commensal flora

International immunology, 2007-03, Vol.19 (3), p.257-265

2007

Volltextzugriff (PDF)

Минимална неуролошка дисфункција и лоше држање тела у деце предшколског узраста

Galić, Maja

2017

Volltextzugriff (PDF)

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

The Lancet (British edition), 2019-09, Vol.394 (10203), p.1030-1040

2019

Volltextzugriff (PDF)

Secretory Antibodies Do Not Affect the Composition of the Bacterial Microbiota in the Terminal Ileum of 10-Week-Old Mice

Applied and Environmental Microbiology, 2003-04, Vol.69 (4), p.2100-2109

2003

Volltextzugriff (PDF)

Chronic Helicobacter pylori Infection Does Not Significantly Alter the Microbiota of the Murine Stomach

Applied and Environmental Microbiology, 2007-02, Vol.73 (3), p.1010-1013

2007

Volltextzugriff (PDF)

Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study

Journal of the neurological sciences, 2023-12, Vol.455, p.121660, Article 121660

2023

Volltextzugriff (PDF)

Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: Results of the UNITE study

Journal of the neurological sciences, 2023-12, Vol.455, p.121661, Article 121661

2023

Volltextzugriff (PDF)

Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study

Journal of the neurological sciences, 2023-12, Vol.455, p.121112, Article 121112

2023

Volltextzugriff (PDF)

PODRŠKA RODITELJIMA DECE SA DIJABETESOM U VRTIĆU

Krugovi detinjstva - časopis za multidisciplinarna istraživanja detinjstva, 2022-07, Vol.10 (1)

2022

Volltextzugriff (PDF)

Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4189)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study (4371)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Efficacy and Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study (4379)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4240)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2–4 Prior Migraine Preventive Medication Classes (2055)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Efficacy and improvements in disability and quality-of-life with fremanezumab over 6 months in migraine patients with inadequate response by multiple prior preventive treatment classes

Journal of the neurological sciences, 2021-10, Vol.429, p.119290, Article 119290

2021

Volltextzugriff (PDF)

Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medication Classes: Results of the Randomized, Placebo-controlled FOCUS Study (4339)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Headache, 2021-04, Vol.61 (4), p.662-672

2021

Volltextzugriff (PDF)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Headache, 2020-11, Vol.60 (10), p.2444-2453

2020

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(100)
Croatian
(12)
Serbian
(2)
Deutsch
(1)
Bulgarisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(44)
Animals
(14)
Female
(13)
Humans
(12)
Male
(10)
Biochemistry & Molecular Biology
(8)
Biotechnology & Applied Microbiology
(8)
Social Sciences
(8)
Clinical Neurology
(7)
Neurosciences & Neurology
(7)
Patients
(7)
Food Science & Technology
(6)
Mice
(6)
Middle Aged
(6)
Technology
(6)
Adult
(5)
Croatia
(5)
Headache
(5)
Medicine
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Optimization of Pretreatment Conditions and Enzymatic Hydrolysis of Corn Cobs for Production of Microbial Lipids by Trichosporon oleaginosus

Lipid production by Mortierella isabellina from pretreated corn cobs and effect of lignocellulose derived inhibitors on growth and lipid synthesis

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Selenite as a Lipid Inductor in Marine Microalga Dunaliella tertiolecta: Comparison of One-Stage and Two-Stage Cultivation Strategies

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

Nanosized zeolite beta - Determining the safety of usage by zebrafish Danio rerio embryos

Minor neurological dysfunction in children aged 5 to 7

Secretory antibodies reduce systemic antibody responses against the gastrointestinal commensal flora

Минимална неуролошка дисфункција и лоше држање тела у деце предшколског узраста

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Secretory Antibodies Do Not Affect the Composition of the Bacterial Microbiota in the Terminal Ileum of 10-Week-Old Mice

Chronic Helicobacter pylori Infection Does Not Significantly Alter the Microbiota of the Murine Stomach

Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study

Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: Results of the UNITE study

Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study

PODRŠKA RODITELJIMA DECE SA DIJABETESOM U VRTIĆU

Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4189)

Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study (4371)

Efficacy and Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study (4379)

Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4240)

Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2–4 Prior Migraine Preventive Medication Classes (2055)

Efficacy and improvements in disability and quality-of-life with fremanezumab over 6 months in migraine patients with inadequate response by multiple prior preventive treatment classes

Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medication Classes: Results of the Randomized, Placebo-controlled FOCUS Study (4339)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Suchergebnisse filtern